CLINICAL AND BIOCHEMICAL EFFECTS OF VERAPAMIL ADMINISTRATION TO SCHIZOPHRENIC-PATIENTS

dc.contributor.authorPICKAR, D
dc.contributor.authorWOLKOWITZ, OM
dc.contributor.authorDORAN, AR
dc.contributor.authorLABARCA, R
dc.contributor.authorROY, A
dc.contributor.authorBREIER, A
dc.contributor.authorNARANG, PK
dc.date.accessioned2025-01-23T19:25:57Z
dc.date.available2025-01-23T19:25:57Z
dc.date.issued1987
dc.description.abstractWe administered verapamil hydrochloride, a calcium channel antagonist, to seven chronically ill schizophrenic patients for five weeks under double-blind, placebo-controlled conditions. No therapeutic effect was noted. Worsening in hostile and uncooperative behaviors and a syndrome of heightened emotional tone was observed during verapamil treatment and during the postverapamil placebo period. Verapamil produced significant increases in cerebrospinal fluid (CSF) and plasma levels of homovanillic acid and in plasma level of prolactin, as well as significant decreases in plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol. Verapamil and its active metabolite, norverapamil, were partitioned into CSF with CSF/plasma ratios of 0.06 and 0.04, respectively. The lack of therapeutic effects of verapamil of schizophrenic patients differ from earlier reports of its usefulness in treating manic patients. The biochemical and clinical data from our study suggest the possibility that verapamil exerts behaviorally relevant central nervous system activity in schizophrenic patients.
dc.fuente.origenWOS
dc.identifier.eissn1538-3636
dc.identifier.issn0003-990X
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/99545
dc.identifier.wosidWOS:A1987F890900001
dc.issue.numero2
dc.language.isoen
dc.pagina.final118
dc.pagina.inicio113
dc.revistaArchives of general psychiatry
dc.rightsacceso restringido
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleCLINICAL AND BIOCHEMICAL EFFECTS OF VERAPAMIL ADMINISTRATION TO SCHIZOPHRENIC-PATIENTS
dc.typeartículo
dc.volumen44
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files